shutterstock_17556916_-ouh_desire

Ouh Desire / Shutterstock.com

30 September 2019BiotechnologyRichard Wells and Stephanie Pilkington

Dosage patents: Down the hatch

The Supreme Court judgment on March 27, 2019 in Actavis v ICOS UK concerned ICOS’s EP (UK) 1 173 181, exclusively licensed to Eli Lilly, and found it invalid for lack of inventive step in the face of Actavis’, and others’, revocation challenge.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Sarepta wins $115M in patent dispute over muscular dystrophy drug

CREATES Act unfairly tips the scales to generics

How Inhibrx defended a $450m damages suit

Foley & Lardner adds litigation and transaction expert in New York

Judge denies Intellia bid to throw out suit over $100m Regeneron pact

Trump’s return sparks calls for pro-patent agenda

Amgen faces pushback over bid to narrow patent scope

LSPN Europe: Navigating the EPO and lessons from the UPC frontline